General Information of the Drug (ID: M6APDG01756)
Name
Carboxylated glucosamine
Synonyms
carboxylated glucosamine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C13H23NO7
InChI
1S/C13H23NO7/c1-2-7-8(5-15)21-9(6-16)12(13(7)20)14-10(17)3-4-11(18)19/h7-9,12-13,15-16,20H,2-6H2,1H3,(H,14,17)(H,18,19)/t7-,8-,9+,12+,13+/m1/s1
InChIKey
PTKIBGLZJSEXPT-KOOJSXSQSA-N
PubChem CID
44411803
TTD Drug ID
D03ZDZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-9 (MMP-9)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Carboxylated glucosamine. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Carboxylated glucosamine through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Carboxylated glucosamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carboxylated glucosamine through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [2], [3]
References
Ref 1 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 2 Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100. doi: 10.1016/j.bmcl.2006.03.065. Epub 2006 May 2.
Ref 3 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.